D-cycloserine (DCS) has been used for decades to treat Mycobacterium tuberculosis (Mtb) but resistance is rarely observed in clinical isolates. Here, the authors report ultra-low rate of emergence of resistance mutations as the underlying mechanism of DCS resistance evasion in Mtb.
- Dimitrios Evangelopoulos
- Gareth A. Prosser
- Luiz Pedro S. de Carvalho
